Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: A strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2

Journal of Pharmaceutical Sciences

Volumn 101, Issue 5, 2012, Pages 1888-1897

  Mease, Kirsten ^a   Sane, Rucha ^a   Podila, Lalitha ^a   Taub, Mitchell E ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

ABC transporters; Active transport; Caco 2 cells; in vitro models; Intestinal absorption; MDCK cells; Membrane transporter; Multidrug resistance transporters; Transporters; P glycoprotein

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DIGOXIN; ESTRONE SULFATE; FUMITREMORGIN C; GENISTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL; VERLUKAST; ZOSUQUIDAR; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; TUMOR PROTEIN; VINBLASTINE;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG TRANSPORT; MEMBRANE PERMEABILITY; MONOLAYER CULTURE; PROTEIN EXPRESSION; ANIMAL; CELL STRAIN CACO 2; DOG; HUMAN; METABOLISM;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CACO-2 CELLS; DOGS; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; VINBLASTINE;

EID: 84864299679     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23069     Document Type: Article

References (47)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 1999. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
2. Gottesman MM, Pastan I. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
3. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95(26):15665-15670.
4. Wakabayashi K, Tamura A, Saito H, Onishi Y, Ishikawa T. 2006. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab Rev 38(3):371-391.
5. Büchler M, König J, Brom M, Kartenbeck J, Spring H, Horie T, Keppler D. 1996. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 271(25):15091-15098.
6. Keppler D, Kartenbeck J. 1996. The canalicular conjugate export pump encoded by the cmrp/cmoat gene. Prog Liver Dis 14:55-67.
7. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, Tytgat GN, Borst P, Baas F, Oude Elferink RP. 1997. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25(6):1539-1542.
8. Chan LM, Lowes S, Hirst BH. 2004. The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21(1):25-51.
9. Hoffmann U, Kroemer HK. 2004. The ABC transporters MDR1 and MRP2: Multiple functions in disposition of xenobiotics and drug resistance. Drug Metab Rev 36(3-4):669-701.
10. Fischer V, Einolf HJ, Cohen D. 2005. Efflux transporters and their clinical relevance. Mini Rev Med Chem 5(2):183-195.
11. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. 1999. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99(4):552-557.
12. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215-236.
13. Su Y, Hu P, Lee SH, Sinko PJ. 2007. Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. J Pharm Pharm Sci 10(4):519-536.
14. Sharom FJ. 2008. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9(1):105-127.
15. Zhang HX, Wang LS. 2008. Effect of genetic polymorphism on the activity of drug transporters and its clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban 33(8):765-769.
16. Burton PS, Conradi RA, Hilgers AR, Ho NF. 1993. Evidence for a polarized efflux system for peptides in the apical membrane of Caco-2 cells. Biochem Biophys Res Commun 190(3):760-766.
17. Elsby R, Surry DD, Smith VN, Gray AJ. 2008. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 38(7-8):1140-1164.
18. Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, Masungi C, Maubon N, Mols R, Mullertz A, Monkkonen J, O'Driscoll C, Oppers-Tiemissen HM, Ragnarsson EG, Rooseboom M, Ungell AL. 2008. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 35(5):383-396.
19. Sun H, Chow EC, Liu S, Du Y, Pang KS. 2008. The Caco-2 cell monolayer: Usefulness and limitations. Expert Opin Drug Metab Toxicol 4(4):395-411.
20. Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland WC, Friedberg T. 2002. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 64(11):1569-1578.
21. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299(2):620-628.
22. Keppler D, Jedlitschky G, Leier I. 1998. Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol 292:607-616.
23. Kalvass JC, Pollack GM. 2007. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: Implications for understanding and predicting the effects of efflux inhibition. Pharm Res 24(2):265-276.
24. Acharya P, O'Connor MP, Polli JW, Ayrton A, Ellens H, Bentz J. 2008. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells. Drug Metab Dispos 36(2):452-460.
25. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ. 1996. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56(18):4171-4179.
26. Mouly SJ, Paine MF, Watkins PB. 2004. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J Pharmacol Exp Ther 308(3):941-948.
27. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. 2000. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60(1):47-50.
28. Shepard RL, Cao J, Starling JJ, Dantzig AH. 2003. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103(1):121-125.
29. Gekler V, Ise W, Sanders K, Ulrich W, Beck J. 1995. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208(1):345-352.
30. Jia JX, Wasan KM. 2008. Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-d-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells. J Pharm Pharm Sci 11(3):45-62.
31. Leyers S, Hacker HG, Wiendlocha J, Gutschow M, Wiese M. 2008. A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins. Bioorg Med Chem Lett 18(17):4761-4763.
32. Yao HM, Chiou WL. 2006. The complexity of intestinal absorption and exsorption of digoxin in rats. Int J Pharm 322(1-2):79-86.
33. Lalloo AK, Luo FR, Guo A, Paranjpe PV, Lee SH, Vyas V, Rubin E, Sinko PJ. 2004. Membrane transport of camptothecin: Facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2). BMC Med 2:16-28.
34. Taub ME, Podila L, Ely D, Almeida I. 2005. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: Influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos 33(11):1679-1687.
35. Lai Y, Xing L, Poda GI, Hu Y. 2007. Structure-activity relationships for interaction with multidrug resistance protein 2 (ABCC2/MRP2): The role of torsion angle for a series of biphenyl-substituted heterocycles. Drug Metab Dispos 35(6):937-945.
36. Xia CQ, Liu N, Yang D, Miwa G, Gan LS. 2005. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 33(5):637-643.
37. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. 2004. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 143(7):856-864.
38. Luna-Tortos C, Fedrowitz M, Loscher W. 2010. Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 58(7):1019-1032.
39. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28(6):655-660.
40. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV. 1997. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A 94(20):10594-10599.
41. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. 2000. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58(3):624-632.
42. Wang Q, Strab R, Kardos P, Ferguson C, Li J, Owen A, Hidalgo IJ. 2008. Application and limitation of inhibitors in drug-transporter interactions studies. Int J Pharm 356(1-2):12-18.
43. Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P. 2009. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26(8):1816-1831.
44. Huisman MT, Chhatta AA, van TO, Beijnen JH, Schinkel AH. 2005. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 116(5):824-829.
45. Letschert K, Faulstich H, Keller D, Keppler D. 2006. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 91(1):140-149.
46. Ballatori N. 2005. Biology of a novel organic solute and steroid transporter, OSTalpha-OSTbeta. Exp Biol Med (Maywood) 230(10):689-698.
47. Gram LK, Rist GM, Lennernas H, Steffansen B. 2009. Impact of carriers in oral absorption: Permeation across Caco-2 cells for the organic anions estrone-3-sulfate and glipizide. Eur J Pharm Sci 37(3-4):378-386.